These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 3360698)

  • 1. In-vitro sensitivity of legionellas and mycoplasmas to amifloxacin.
    Fallon RJ
    J Antimicrob Chemother; 1988 Mar; 21(3):381-2. PubMed ID: 3360698
    [No Abstract]   [Full Text] [Related]  

  • 2. In-vitro sensitivity of legionellas, meningococci and mycoplasmas to ciprofloxacin and enoxacin.
    Fallon RJ; Brown WM
    J Antimicrob Chemother; 1985 Jun; 15(6):787-9. PubMed ID: 3161857
    [No Abstract]   [Full Text] [Related]  

  • 3. In-vitro activity of gatifloxacin, a novel fluoroquinolone, compared with that of ciprofloxacin against Legionella spp.
    Pendland SL; Losnedahl KJ; Schriever CA
    J Antimicrob Chemother; 1999 Aug; 44(2):295-7. PubMed ID: 10473243
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro susceptibility of avian mycoplasmas to enrofloxacin, sarafloxacin, tylosin, and oxytetracycline.
    Wang C; Ewing M; Aarabi SY
    Avian Dis; 2001; 45(2):456-60. PubMed ID: 11417828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of amifloxacin against Chlamydia trachomatis and Ureaplasma urealyticum.
    Freeman S; Wormuth J; Cornett J
    Eur J Clin Microbiol; 1985 Oct; 4(5):515-6. PubMed ID: 4065142
    [No Abstract]   [Full Text] [Related]  

  • 6. Susceptibility of non-fermentative gram-negative bacteria to ciprofloxacin, norfloxacin, amifloxacin, pefloxacin and cefpirome.
    Appelbaum PC; Spangler SK; Sollenberger L
    J Antimicrob Chemother; 1986 Dec; 18(6):675-9. PubMed ID: 3469178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility of mycoplasmas to a new quinolone, BAY Y 3118.
    Renaudin H; Bébéar C
    Drugs; 1995; 49 Suppl 2():243-5. PubMed ID: 8549318
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.
    Pereyre S; Renaudin H; Bébéar C; Bébéar CM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3165-8. PubMed ID: 15273141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Legionella pneumophila multiplication within human macrophages by fleroxacin.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():49-54. PubMed ID: 3144549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vitro investigation of the intraphagocytic bioactivity of difloxacin, ciprofloxacin, pefloxacin and fleroxacin.
    van Rensburg CE; Joone G; Anderson R
    Chemotherapy; 1989; 35(4):273-7. PubMed ID: 2504545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of three new fluoroquinolones.
    Coll R; Esteve M; Moros M; Parés J; Xicota MA
    Chemioterapia; 1987 Jun; 6(2 Suppl):152-3. PubMed ID: 3509374
    [No Abstract]   [Full Text] [Related]  

  • 12. Fleroxacin (Ro 23-6240): activity in vitro against 355 enteropathogenic and non-fermentative gram-negative bacilli and Legionella pneumophila.
    Hohl P; von Graevenitz A; Zollinger-Iten J
    J Antimicrob Chemother; 1987 Sep; 20(3):373-8. PubMed ID: 3119553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amifloxacin distribution in the dog prostate.
    Frimodt-Møller PC; Dørflinger T; Madsen PO
    Prostate; 1985; 6(2):163-8. PubMed ID: 3975177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of in vitro activity of daptomycin, vancomycin and fluoroquinolones in broth and serum against Staphylococcus epidermidis as determined by time-kill kinetics.
    Lentino JR; Strodthman R
    Chemotherapy; 1989; 35(3):168-73. PubMed ID: 2548817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antimicrobial susceptibility patterns of Legionella isolates in the environment and in patients].
    Choi GE; Kang JE; Lee EY; Chang CL; Tateda K; Yamaguchi K; Kim KH; Kim JM
    Korean J Lab Med; 2010 Feb; 30(1):28-33. PubMed ID: 20197719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of fluoroquinolone (ciprofloxacin) resistance in Mycoplasma hominis in the presence of Hela cells].
    Momynaliev KT; Smirnova OV; Ladygina VG; Orlova VF; Akopian TA; Govorun VM
    Genetika; 2002 Jul; 38(7):922-8. PubMed ID: 12174584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():35-41. PubMed ID: 3144547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory and bactericidal activities of amifloxacin, a new quinolone carboxylic acid, compared with those of seven other antimicrobial agents.
    Baltch AL; Sutphen NT; Smith RP; Conley PE
    Clin Ther; 1984; 7(1):73-80. PubMed ID: 6440708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis.
    Furneri PM; Bazzano M; Campo L; Cesana M; Tempera G
    Chemotherapy; 1994; 40(2):104-8. PubMed ID: 8131632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.